Tempest Therapeutics, Inc. TPST

Tempest Therapeutics named Nancy Freda-Smith to its board as Chair of the Audit Committee. A 30-year public-company finance and governance veteran, she previously led audit and risk at Ralph Lauren and held roles with Deloitte and Chuy's Holdings. Her appointment adds governance, financial reporting, enterprise risk management, and capital-planning oversight to Tempest as it advances its in vivo CAR-T program, including lead candidate TPST-4003 (CD19/BCMA CAR with CD7 delivery). Tempest aims to broaden its pipeline and strategic partnerships while executing on its development plans and maintaining strong financial controls. The news underscores the company's focus on governance as it pursues clinical development and potential partnerships. Brings seasoned public-company finance, audit, and governance expertise to Tempest, improving oversight and capital management.

Tempest Therapeutics secured an exclusive option to license a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform. Option to license clinical-stage CAR-T platform represents major strategic move strengthening Tempest pipeline and market position.

Tempest Therapeutics, Inc. (TPST) announces private placement financing of up to $7.5 million. Private placement supplies Tempest Therapeutics with up to $7.5 million in additional capital.

Tempest Therapeutics reported second quarter 2026 financial results and provided a business update. Quarterly financial results and business updates typically influence near-term market sentiment and valuation without fundamentally redefining long-term strategy.

Tempest Therapeutics announces development collaboration with Senlang Biotechnology for TPST-4003, a CD7-targeted next-generation in vivo CAR-T. Collaboration advances novel CAR-T candidate and expands Tempest pipeline with next-gen in vivo technology.

Tempest Therapeutics unveils next-generation in vivo CAR-T pipeline. First clinical study planned for fourth quarter of 2026. Pipeline unveiling and 2026 clinical study plans mark major strategic progress in Tempest's therapeutic development.

Tempest Therapeutics, Inc. (TPST) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business update moderately influence financial performance and investor sentiment.

Tempest Therapeutics, Inc. (TPST) presented a clinical update at the ISCT 2026 Annual Meeting. Clinical update presentations at major conferences like ISCT moderately influence biotech investor sentiment and competitive positioning.

Tempest Therapeutics advances dual-targeting CAR-T platform with clinical update presentation at ISCT 2026 Annual Meeting. Clinical update on dual-targeting CAR-T platform at major conference signals significant pipeline progress and potential competitive edge in oncology.

Tempest Therapeutics, Inc. (TPST) announces key manufacturing milestone for TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy. Manufacturing milestone for lead dual-targeting CAR-T candidate de-risks development, accelerates clinical path, and enhances competitive positioning in oncology.

Tempest Therapeutics, Inc. (TPST) reported year-end 2025 financial results and provided a business update. Year-end financial results and business updates typically affect financial performance and market sentiment but are balanced by pipeline details.

Tempest Therapeutics, Inc. (TPST) announces a private placement to raise up to $6 million. Up-to-$6-million private placement extends financial runway and supports clinical development amid biotech funding needs.

Tempest Therapeutics announces partnership for TPST-2003 to prepare for planned U.S. registrational study in 2026. Partnership validates TPST-2003 and supports pivotal registrational study, signaling major progress toward potential approval and commercialization.

Tempest Therapeutics announces interim results from the ongoing REDEEM-1 trial of TPST-2003 and is preparing for a potential U.S. registrational study in 2026. Interim trial results and preparation for registrational study represent major clinical advancement for TPST-2003, likely boosting investor sentiment and stock performance.

Tempest Therapeutics, Inc. has outlined a strategic plan to advance its recently acquired dual-targeting CAR-T assets. The company aims to leverage these assets to enhance its position in the competitive CAR-T therapy market, focusing on innovative treatment options for patients with cancer. This strategic move is expected to drive future growth and improve market performance. The strategic plan to advance dual-targeting CAR-T assets is likely to significantly impact Tempest's future performance and market positioning.

Tempest Therapeutics, Inc. has successfully completed the acquisition of dual-targeting CAR-T assets, a strategic move aimed at enhancing its product pipeline and competitive positioning in the CAR-T therapy market. This acquisition is expected to bolster Tempest's capabilities in developing innovative treatments for cancer, aligning with its long-term growth strategy. The acquisition of dual-targeting CAR-T assets is a significant strategic move that could enhance Tempest's product offerings and market position.

Tempest Therapeutics, Inc. has announced the record date for an anticipated dividend distribution of warrants to its stockholders. This move is part of the company's strategy to enhance shareholder value and engage investors. The specific details regarding the distribution and its implications for stockholders were outlined in the announcement. The distribution of warrants may influence investor sentiment and shareholder engagement, but its overall effect on the company's trajectory is expected to be limited.

Tempest Therapeutics, Inc. has completed a registered direct offering of common stock, raising up to $8.35 million, alongside a concurrent private placement of warrants. The offering was priced at-the-market under Nasdaq rules, allowing the company to strengthen its financial position. The capital raised may support future operations and initiatives, but the overall impact on the company's trajectory is expected to be limited.

Tempest Therapeutics, Inc. announced a registered direct offering of common stock and a concurrent private placement of warrants, potentially raising up to $8.35 million. The offering is priced at-the-market under Nasdaq rules, aiming to enhance the company's financial position. The capital raise may provide necessary funding for operations and development, impacting financial performance moderately.

Tempest Therapeutics, Inc. has announced the strategic acquisition of new dual-CAR T programs from Factor, which is expected to extend its operational runway to mid-2027. This move aims to enhance Tempest's product pipeline and strengthen its position in the competitive landscape of CAR T therapies. The acquisition of new dual-CAR T programs is a significant strategic move that could enhance Tempest's product offerings and market position.

Tempest Therapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and updates on its business operations. The company provided insights into its ongoing projects and strategic initiatives aimed at enhancing its market position. Financial performance indicators showed trends that may influence future growth and investor sentiment. The financial results and business updates indicate a moderately noticeable influence on the company's future performance and market positioning.

Tempest Therapeutics, Inc. reported its financial results for the second quarter of 2025, highlighting key metrics and developments in its business operations. The company provided updates on its ongoing projects and strategic initiatives aimed at enhancing its market position and financial performance. Management expressed optimism about future growth prospects and outlined plans for upcoming product launches and research advancements. Significant strategic moves and product developments are expected to impact the company's trajectory and investor sentiment.

Tempest Therapeutics, Inc. has received approval from China's National Medical Products Administration to initiate a pivotal trial for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). This trial builds on previous clearances from the FDA and EMA and aims to address the high prevalence of HCC in China. The Phase 3 study will compare the combination therapy against the standard of care. Amezalpat has shown clinical superiority in earlier studies, suggesting it could significantly impact patient outcomes. Regulatory approval for a pivotal trial in a high-prevalence market like China is a significant strategic move that could enhance Tempest's market position and investor sentiment.

Tempest Therapeutics, Inc. has received Orphan Drug Designation from the European Medicines Agency for Amezalpat, aimed at treating patients with hepatocellular carcinoma (HCC). This designation is intended to facilitate the development of Amezalpat, providing various benefits including market exclusivity in the EU for a period of time upon approval. Orphan Drug Designation can significantly enhance the development and market potential of Amezalpat, impacting the company's future performance.

Tempest Therapeutics, Inc. reported its Q1 2025 financial results, highlighting new data on amezalpat's mechanism of action presented at the AACR Annual Meeting. The company received FDA Orphan Drug designation for TPST-1495 for familial adenomatous polyposis and both Orphan Drug and Fast Track designations for amezalpat for hepatocellular carcinoma. Tempest ended the quarter with $21.5 million in cash, down from $30.3 million at the end of 2024, and reported a net loss of $10.9 million. The company is exploring strategic alternatives to enhance stockholder value and has reduced its workforce. Significant regulatory designations and promising clinical data could substantially impact Tempest's future performance and investor sentiment.

Tempest Therapeutics, Inc. presented new data at the 2025 AACR Annual Meeting supporting the immune-mediated dual mechanism of action of amezalpat, a novel cancer treatment. The data indicated that amezalpat reduces tumor-promoting immunosuppression by M2 macrophages and T regulatory cells, leading to immune activation. Clinical trials showed promising results in patients with hepatocellular carcinoma, renal cell carcinoma, and cholangiocarcinoma, particularly when combined with approved immunotherapies. Amezalpat acts as a selective PPAR-alpha antagonist, targeting both tumor cells and immune suppressive cells. The company is advancing its portfolio of cancer therapies and is headquartered in Brisbane, California. The presentation of significant clinical data and the potential for amezalpat to alter treatment paradigms in cancer therapy indicate a major strategic move for the company.

Tempest Therapeutics, Inc. has received Orphan Drug Designation from the FDA for its investigational drug TPST-1495, aimed at treating patients with Familial Adenomatous Polyposis (FAP). This designation is intended to facilitate the development of therapies for rare diseases, providing Tempest with potential benefits such as tax incentives and market exclusivity upon approval. The Orphan Drug Designation could significantly enhance Tempest's strategic position and investor sentiment by accelerating the development of TPST-1495 for a rare condition.

Tempest Therapeutics, Inc. announced plans to explore strategic alternatives aimed at advancing its clinical oncology pipeline and maximizing stockholder value. The company is considering various options to enhance its operations and financial performance, reflecting its commitment to developing innovative cancer therapies. Exploring strategic alternatives could significantly impact the company's future direction and investor sentiment.

Tempest Therapeutics, Inc. reported significant advancements in 2024, including Orphan Drug and Fast Track designations for Amezalpat (TPST-1120) in treating Hepatocellular Carcinoma (HCC) and an agreement with Roche for a pivotal Phase 3 trial. The company also received FDA approval to proceed with a Phase 2 trial for TPST-1495 targeting Familial Adenomatous Polyposis (FAP). Financially, Tempest ended the year with $30.3 million in cash, down from $39.2 million, and reported a net loss of $41.8 million. Research and development expenses rose significantly due to preparations for the Phase 3 trial of Amezalpat. The receipt of regulatory designations and partnership with Roche for pivotal trials are major strategic moves that could significantly impact Tempest's future performance.

Tempest Therapeutics, Inc. announced a poster presentation for Amezalpat at the 2025 American Association for Cancer Research (AACR) Annual Meeting. This presentation will highlight the latest findings and developments related to Amezalpat, a key asset in Tempest's pipeline, aimed at advancing cancer treatment options. The presentation could enhance visibility and interest in Amezalpat, potentially influencing investor sentiment and market performance.